ReviewAdvanced drug delivery reviews2009
Lipid-based systemic delivery of siRNA.
Review in Advanced drug delivery reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 462 citations in OpenAlex.
- Cationic lipid-based nanoparticles for therapeutic delivery in cancer treatment: physicochemical characteristics, therapeutic cargos, and clinical potential.Applied microscopy · 2026Review
- Biomaterial-Based Nucleic Acid Delivery Systems for In Situ Tissue Engineering and Regenerative Medicine.International journal of molecular sciences · 2025Review
- Recent Update on siRNA Therapeutics.International journal of molecular sciences · 2025Review
- A Chemoinformatic-Guided Synthesis of a Spleen-Expressing mRNA Lipid Nanoparticle Platform.Bioconjugate chemistry · 2025Article
- Microfluidic Synthesis of miR-200c-3p Lipid Nanoparticles: Targeting ZEB2 to Alleviate Chondrocyte Damage in Osteoarthritis.International journal of nanomedicine · 2025Article
- Review
- RNA Interference Applied to Crustacean Aquaculture.Biomolecules · 2024Review
- Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair.Journal of nanobiotechnology · 2024Review
- Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy.Acta pharmaceutica Sinica. B · 2023Article
- Role of long non-coding RNAs in cancer: From subcellular localization to nanoparticle-mediated targeted regulation.Molecular therapy. Nucleic acids · 2023Review
- The emerging potential of siRNA nanotherapeutics in treatment of arthritis.Asian journal of pharmaceutical sciences · 2023Review
- Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis.Acta pharmaceutica Sinica. B · 2023Article
- Microfluidics for nano-drug delivery systems: From fundamentals to industrialization.Acta pharmaceutica Sinica. B · 2023Review
- Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification.Bioengineering (Basel, Switzerland) · 2023Article
- Does Patisiran Reduce Ocular Transthyretin Synthesis? A Pilot Study of Two Cases.Current neuropharmacology · 2023Article
- Recent advancements of miRNAs in the treatment of bone diseases and their delivery potential.Current research in pharmacology and drug discovery · 2023Review
- Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy.Bioengineering (Basel, Switzerland) · 2022Review
- Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy.Exploration (Beijing, China) · 2022Article
- Artificial stem cells mediated inflammation-tropic delivery of antiviral drugs for pneumonia treatment.Journal of nanobiotechnology · 2022Article
- Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias.Journal of clinical medicine · 2022Review
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
RNAi technology has brought a new category of treatments for various diseases including genetic diseases, viral diseases, and cancer. Despite the great versatility of RNAi that can down regulate almost any protein in the cells, the delicate and precise machinery used for silencing is the same. The major challenge indeed for RNAi-based therapy is the delivery system. In this review, we start with the uniqueness and mechanism of RNAi machinery and the utility of RNAi in therapeutics. Then we discuss the challenges in systemic siRNA delivery by dividing them into two categories-kinetic and physical barriers. At the end, we discuss different strategies to overcome these barriers, especially focusing on the step of endosome escape. Toxicity issues and current successful examples for lipid-based delivery are also included in the review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.